AGM/EGMJun 4, 2026, 06:07 AM
Denali Therapeutics Stockholders Elect Directors, Ratify Auditor
AI Summary
Denali Therapeutics Inc. held its annual meeting on June 3, 2026, with 86.96% of outstanding common stock represented. Stockholders elected three Class III directors: Jennifer Cook, David Schenkein, M.D., and Ryan Watts, Ph.D., to serve until the 2029 annual meeting. Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026 was ratified, and the advisory vote to approve executive compensation was passed.
Key Highlights
- Annual meeting held on June 3, 2026, with 86.96% of outstanding shares represented.
- Jennifer Cook elected Class III director with 75,998,259 votes For.
- David Schenkein, M.D., elected Class III director with 91,814,688 votes For.
- Ryan Watts, Ph.D., elected Class III director with 121,220,572 votes For.
- Ernst & Young LLP ratified as independent auditor with 137,516,267 votes For.
- Advisory vote to approve executive compensation passed with 117,038,745 votes For.
Price Impact
More from DNLI